Single Cell Minimal Residual Disease Analysis in Multiply Relapsed AML Patient

This patient experienced multiple AML relapses, yet demonstrated exceptional response to the small molecule IDH1 inhibitor Olutasidenib. To further study both the disease and treatment biology specific to this patient, we used a novel single cell AML MRD assay to perform both single cell DNA and protein-level analysis. Overall design: Cryopreserved Bone Marrow Mononuclear Cells (BMMC) from a multiply relapsed AML patient were CD34 and CD117 enriched, and then underwent single cell DNA and protein sequencing for minimal residual disease (MRD) analysis.